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Key points: 
 
 Approximately 2.75 million (15.4%) Australians aged ≥15 years are estimated to 
have chronic and reoccurring pain (over a six-month period) based on the most 
comprehensive, nationally representative health survey conducted in Australia. 
 Recent use of opioid analgesic medications was reported by 12.0% of males and 
13.4% of females with chronic pain. Persons using opioid analgesia primarily 
reported moderate to very severe pain. 
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Abstract 
 
Background: Opioid analgesic use and associated adverse events have increased over the 
last 15 years, including in Australia. Whether this is associated with increased chronic pain 
prevalence in the Australian population is unknown. This study aimed to estimate: (1) 
prevalence of chronic pain and analgesia use in the Australian population by age and sex; (2) 
severity of pain in the population with chronic pain by sex; and (3) the distribution of recent 
pain severity in those using analgesia by age and sex. 
Methods: This study used cross-sectional, nationally representative data collected by the 
Australian Bureau of Statistics 2011-12 National Health Survey. A total of n=20,426 
participants were included with an overall response rate of 84.8%. Weighting procedures 
were applied to obtain population estimates, confidence intervals and when testing for 
statistical significance. 
Results: The prevalence of chronic and reoccurring pain (over a six-month period) was 
15.4% (2.75 million) for Australians aged ≥15 years. Prevalence increased with age for both 
sexes. Significantly more females reported moderate-to-very severe pain overall (p <0.001), 
and within most age groups. Recent use of opioid analgesia was reported by 12.0% of males 
and 13.4% of females with chronic pain. 
Conclusion: Chronic pain and opioid analgesic use are important public health issues in 
Australia. Study estimates of chronic pain and recent pain were no greater than earlier 
estimates. The acknowledged increase of opioid use in the literature thus appears 
consistent with changing treatment and/or prescribing patterns over time. Sex differences 
regarding pain prevalence, severity and opioid use were apparent. 
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1. Introduction 
 
Effective management of chronic pain generally encompasses several treatment modalities 
incorporated within a multi-disciplinary framework [1]. Though efficacy has been debated, 
opioid analgesic medications have been increasingly prescribed for chronic pain over the 
last two decades [2]. During this time, numerous studies have identified an escalation in 
opioid analgesic medication use and associated adverse events, both in Australia and 
internationally [3-7]. Studies have also noted differences between the sexes in patterns of 
use, misuse and adverse events associated with opioid analgesic medications [8, 9], with a 
review by Darnall, Stacey and Chou (2012) recently expressing ‘there is a major need for all 
opioid studies to examine data by sex’ [9]. One reason is that, internationally, use of opioid 
analgesia in women of reproductive age has become an epidemic [10, 11] and if use is 
continued during pregnancy, this can adversely affect infant outcomes [10, 12]. Further, 
many studies have indicated that there is an increased frequency of chronic pain [13, 14] 
and specific chronic pain conditions in females [8, 9]. However, other studies have found no 
significant differences in the prevalence of chronic pain between males and females [15, 
16]. 
In Australia and elsewhere opioid analgesia is generally indicated for pain that is considered 
moderate to severe [17-19]. Thus, in addition to pain of extended duration as reflected by 
chronic pain status, information on pain severity should also be assessed to ensure use is 
consistent with prescribing recommendations. As a counterpoint, equivalent data on non- 
opioid analgesia can provide further insight into the use of opioid analgesics in recent pain, 
by severity and in those with chronic pain. Whether the increased use of opioid analgesia in 
the Australian population is associated with a change in chronic pain prevalence over time, 
or is solely associated with other factors is currently unknown. Furthermore, an assessment 
of the appropriateness of opioid analgesia use in association with pain severity, given 
current prescribing recommendations, is also needed. Therefore, using the Australian 
National Health Survey (NHS) this study will (1) estimate current prevalence of chronic pain 
and analgesia use in the Australian population by and age and sex; (2) determine severity of 
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pain in the population with chronic pain by sex; and (3) assess the distribution of recent pain 
severity in those using analgesia, by age and sex. 
2. Methods 
 
2.1 Participants 
 
This study used cross-sectional, nationally representative data collected by the Australian 
Bureau of Statistics (ABS) in the 2011-12 Australian NHS. The 2011-12 Australian NHS is the 
sixth of its kind conducted by the ABS since 1989, with the aim of establishing national 
benchmarks on many health related issues and health trends over time [20]. The sample 
consisted of persons of all ages living in private Australian residences, collected via stratified 
multistage sampling [20]. The sample design ensured that within each state of Australia, 
each person had an equal chance of selection. Survey information was obtained for one 
adult and one child aged 0-17 years (if applicable) in each participating household [20]. 
Face-to-face interviews were conducted by trained ABS interviewers in participants’ homes 
between the periods of March 2011 to March 2012 [20]. The overall response rate was 
84.8%, with a total of n=20,426 participants from 15,565 private residences [21]. 
Data are made available by the ABS in the form of a Confidentialised Unit Record File 
(CURF). The CURF contains detailed, individual participant data which has been collected by 
the ABS for the purposes of census and population surveys [12]. This data is made available 
at the discretion of the ABS on the condition that participant identity is not available to 
users of the CURF and participant confidentiality is always retained [12]. For this reason, not 
all data collected within a survey may be included in the CURF and there are restrictions on 
allowable analyses. 
2.2 Data and analysis 
Chronic pain was defined as self-reported pain which persisted or reoccurred over a six- 
month period. ‘Bodily Pain’ was defined as pain experienced within the previous four weeks 
and measured by severity of pain experienced on a scale from ‘no pain’ to ‘very severe’ 
pain. To reflect prescribing recommendations for opioid analgesic medications (treatment of 
moderate to very severe pain), pain severity was classified into four groups: no pain, very 
mild to mild pain, moderate to very severe pain and not applicable or unknown. As chronic 
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pain gives an indication of pain duration and bodily pain provides information on recent 
pain severity, use of both variables allowed investigation of the severity of chronic pain and 
whether opioid analgesia use was appropriately associated with pain severity given 
prescribing recommendations. 
Participants were asked for the name or brand of all medication they had taken in the last 
two weeks and were requested to provide the packages of all recently used medications to 
the interviewer to assist in the recording process. Medications were classified using the 
World Health Organisation’s Anatomical Therapeutic Chemical (ATC) system. To investigate 
associations between analgesia use and pain of all severities, both opioid and non-opioid 
analgesia use were analysed for this study. Opioid analgesia use included the use of any 
type of opioid analgesia over the previous two-week period. Non-opioid analgesia use 
included the use of any type of pharmaceutical non-opioid analgesic medications (e.g. 
paracetamol) and anti-migraine medications. The survey did not differentiate between 
prescribed or ‘over the counter’ analgesic medications within the opioid or non-opioid 
analgesia classifications. 
Data specific to chronic pain was not available in the CURF and was provided directly from 
the ABS by special request. This data included Australian population totals (all ages) as well 
as specific analysis for participants aged ≥15 years. All other analyses were based on data 
extracted from the CURF. Data included individual participants’ age, sex, bodily pain 
(severity), opioid analgesia use and non-opioid analgesia use. These data were analysed for 
participants aged ≥15 years (n=16,412, N=17,894,850), although detailed bodily pain data is 
only available for those aged ≥18 years (n=15,475, N=17,042,208). 
Weighting procedures were applied using STATA v12 to calculate population estimates, 
associated confidence intervals and to test for statistical significance between proportions. 
The Jackknife delete-1 weighting method was used to account for the stratified multistage 
design of the survey, any oversampling and non-response. Differences in proportions of 
males and females were calculated in each age group for bodily pain (severity), opioid 
analgesia use and non-opioid analgesia use [9], with p-values of ≤0.05 considered a 
statistically significant difference. No adjustment was made for conducting multiple tests as 
per Rothman [22]. 
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2.3 Ethics 
 
The interview components of the NHS were conducted by the ABS under the Census and 
Statistics Act 1905. Statistical analysis of the chronic pain data was restricted and as a result 
was conducted directly by the Australian Bureau of Statistics (ABS) for the purposes of this 
study. All analyses of the CURF data were undertaken by AM and MB who are registered 
users of the NHS CURF. 
3. Results 
 
3.1 Chronic pain and analgesia use 
 
Of the total Australian population (N=22,105,281), an estimated 12.7% (N=2.8 million) live 
with chronic or reoccurring pain, increasing to 15.4% (N=2.75 million) when those aged <15 
years were excluded. Of males who were ≥15 years of age, 14.6% were living with chronic or 
reoccurring pain, and likewise for 16.1% of females. 
The distribution of the Australian population aged ≥15 years living with chronic or 
reoccurring pain and the percentages using opioid analgesia by 10-year age groups by sex is 
illustrated in Figure 1. The prevalence of chronic or reoccurring pain generally increased 
with age for both males and females. Over 12% of females ≥85 years reported any opioid 
analgesia use in the two weeks prior to the survey. There was a trend towards higher opioid 
use in females than males in every age group. 
Figure 1 
 
The percentage of those reporting chronic or reoccurring pain and taking opioid analgesia 
are represented in Figure 2a. An estimated 12.0% of males and 13.4% of females with 
chronic or reoccurring pain aged ≥15 years had taken opioid analgesic medications in the 
previous two weeks, with the highest percentages of use seen in the youngest (17.0%) and 
oldest (29.0%) female age groups. The percentages of those reporting chronic or reoccurring 
pain and taking non-opioid analgesia are represented in Figure 2b. In those aged ≥15 years 
almost a quarter (23.1%) of males and over a quarter (29.2%) of females with chronic or 
reoccurring pain had taken non-opioid analgesic medications in the previous two weeks, 
with both males (57.6%) and females (63.9%) aged ≥85 years reporting the highest 
percentages of use. 
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Figure 2a and 2b 
 
 
 
 
 
3.2 Pain severity in persons with chronic pain 
 
The distribution of reported pain severity over the last four weeks in persons aged ≥18 years 
with chronic or reoccurring pain is shown in Table 1. Most males (63.8%) and females 
(72.2%) with chronic or recurring pain stated their pain was moderate to very severe over 
the four weeks prior to the survey. 
 
 
Table 1 
 
3.3 Recent pain severity in persons with bodily pain 
 
Over two thirds (68.2%) of Australians aged ≥18 years (71.1% of females, 65.2% of males) 
reported experiencing pain of any severity over the four weeks prior to the survey, 
with26.6% reporting moderate to very severe pain, 41.5% very mild to mild pain, and 31.1% 
reporting no pain. Pain severity was not applicable or was unknown in the remaining 0.7%. 
One-fifth of those reporting some bodily pain also had chronic or recurring pain. 
When broken down by sex, males were significantly more likely overall to report no pain (p 
<0.001) or be in the not applicable/unknown category (p <0.001), and females were 
significantly more likely to report moderate to very severe pain (p = 0.001). A detailed 
breakdown of pain severity by age group for both males and females is provided in Table 2. 
Table 2 
 
Statistically significant differences were also noted in pain severity experienced by males 
and females within most age ranges across the lifespan. A significantly higher percentage of 
females than males reported moderate to very severe pain within almost every age group 
except 65 to 74 years (15 to 24 years p = 0.006; 25 to 34 years p = 0.008; 35 to 44 years p = 
0.031; 45 to 54 years p = 0.023; 55 to 64 years p = 0.001; 75 to 84 years p <0.001). A 
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significantly higher percentage of males than females reported no pain within ages 45 to 54 
years (p = 0.002), 55 to 64 years (p <0.001) and 75 to 84 years (p = 0.001). A significantly 
higher percentage of males than females aged 65 to 74 years reported very mild to mild 
pain (p = 0.004). 
3.4 Distribution of pain severity in persons using analgesia 
 
Figures 3a and 3b illustrate the distribution of pain severity in males and females aged ≥15 
years using opioid analgesia in the previous two weeks. In each age group, except males 
aged 15 to 24 years, most individuals using opioid analgesia reported moderate to very 
severe pain, followed by very mild to mild pain. However, in males aged 15 to 24 years the 
percentage reporting no pain and having used opioid analgesia in the previous two weeks 
(32.7%) was higher than those reporting very mild to mild pain (13.2%). In no other age 
range did males (or females) report ‘no pain’ while also reporting recent opioid use to the 
extent seen in the youngest male group. There was not enough evidence to reject the null 
hypothesis of no difference between males and females of each age group using opioid 
analgesia for any level of pain severity. 
 
 
Figure 3a and 3b 
 
 
 
Figures 4a and 4b illustrate the distribution of pain severity in males and females overall 
using non-opioid analgesia during the previous two weeks. The highest prevalence of non- 
opioid analgesia use was seen in younger males and females (15 to 44 years) reporting very 
mild to mild pain, and older males and females (≥45 years) with moderate to very severe 
pain. In both younger and older age groups, a small percentage of males and females who 
took non-opioid analgesia reported no pain. Males had a significantly greater percentage 
using non-opioid analgesia in the 45 to 54 year age group reporting no pain (p = 0.024), in 
the 55 to 64 year age group with no pain (p = 0.016) and very mild to mild pain (p = 0.026), 
and the 75 to 84 year age group with no pain (p = 0.006) and very mild to mild pain (p = 
0.009). A significantly higher proportion of females using non-opioid analgesia reported 
moderate to very severe pain in the 75 to 84 year age group (p <0.001). 
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4. Discussion 
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Through the 2011-12 Australian NHS it is estimated that 2.75 million (15.4%) Australians 
aged ≥15 years have chronic or reoccurring pain, comprising 16.1% of females and 14.6% of 
males. Almost three-quarters of females in the group with chronic or reoccurring pain 
reported that their pain had been moderate to very severe in the most recent four-week 
period. Over two thirds of Australians (68.2%) experienced some bodily pain within the 
most recent four-week period, affecting 71.1% of females and 65.2% of males, with one fifth 
also reporting chronic pain. Higher percentages of moderate to very severe pain were 
reported within almost every age group in females compared to males. An estimated one in 
eight persons with chronic pain had taken opioid analgesic medication within two weeks 
prior to the survey, with similar rates of overall use in males and females at 12.0% and 
13.4% respectively. However, the highest reported percentages of opioid analgesia use 
were amongst the youngest (17.0%) and oldest (29.0%) females with chronic pain. In 
contrast, there was a trend of increasing prevalence of chronic pain in persons who 
reported using non-opioid analgesia with age, for both men and women. Most using opioid 
analgesia had experienced moderate to very severe pain over the most recent four-week 
period, except for males aged 15 to 24 years. Pain severity was highly variable in those who 
used non-opioid analgesia. While moderate to very severe pain was reported by 
the majority of non-opioid analgesia users in those aged ≥45 years, this was not the case in 
the younger age groups. 
The percentages of chronic pain in the Australian population identified in this study are no 
greater than those reported over 15 years ago in the primary reference for chronic pain 
prevalence in Australia, Blyth et al. (2001) [14]. The Blyth et al. (2001) study, which was 
based upon a sample drawn from the state of New South Wales in 1999, reported the 
overall prevalence of chronic pain as 20% for females and 17% for males aged 15 to 84 years 
[14]. Similar estimates of chronic pain prevalence, 20% of females and 18% of males, were 
reported in a recent national study on patients, including children, seeking medical 
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treatment from a General Practitioner [16].However, differences in inclusion criteria in the 
study of general practice patients requires these results to be considered stand-alone. 
In interpreting the results of the current study, it is also important to consider variations in 
definitions of chronic pain. The ABS defined chronic pain as self-reported pain which 
persisted or reoccurred over a six month period, similar to the definition used in a recent 
Danish study of population survey data [23]. In contrast, Blyth et al. (2001) and most other 
published Australian studies define chronic pain as pain occurring every day, over a three- 
month period within the most recent six months [14-16, 24]. The ABS definition used for the 
current study is thus arguably less stringent, which would be expected to lead to higher 
estimates of prevalence, rather than the lower estimates observed. Thus, it is apparent that 
the prevalence of chronic pain in the current study is no greater than these earlier 
estimates. In turn, there is no evidence to support an increase in chronic pain prevalence 
since the Blyth et al. (2001) study, and certainly not to the extent of the 15-fold increase in 
opioid analgesia dispensing episodes within the Australian population between 1992 and 
2012 [4]. Further, the increase in opioid use reported in the literature cannot be ascribed to 
an increase in the overall proportion experiencing any bodily pain as the percentage of the 
population aged 18 years and above experiencing any bodily pain has remained constant at 
68% from the 2007-08 NHS [25], to the current study. However, it is possible that an 
increase in pain severity in those with chronic pain over time could account for some of the 
increase in opioid use. 
Many of the other findings noted above also show similarities to those found in the 
published literature. First, the estimate of opioid use in the Australian population with 
chronic pain, at 12% for males and just over 13% for females, and the 12% reported for 
Denmark[26]. Second, the estimate that just over two thirds of all Australians aged ≥18 
years had experienced some pain during the last four weeks, shows some comparability to 
the 55.7% reported for the US population in 2012 [13]. Third, the finding that moderate to 
very severe pain was more prevalent in females across most age groups is consistent with 
previous findings of epidemiological and experimental research[29]. Nahin (2015) also found 
that females in the US population had a higher prevalence of more severe pain, but only in 
specific language and cultural groups [13] Fourth, the majority of those using opioid 
analgesia also reported recent moderate to very severe pain, similar to a large, cross- 
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sectional study of n=10,066 participants in Denmark [30]. This is also consistent with current 
prescribing recommendations in Australia [17] and by the World Health Organisation [18]. 
Also consistent with previous research is the relatively high use of opioid medications in the 
elderly seen in this study [31]. This earlier research found that between 2002 to 2009 
buprenorphine, fentanyl, oxycodone (5mg, both immediate and modified release) and 
tramadol (100mg) dispensing in Australia was highest in females aged 90 to 99 years, even 
with palliative care excluded [32]. Likewise, opioid prescriptions for both morphine and 
oxycodone have been reported as most common among elderly Australians aged ≥80 years 
[3]. Given that opioid use in older people has been associated with an increased risk of 
medication related hospitalisations and numerous adverse events including falls causing 
injury, fracture, dizziness and delirium [4, 27, 28], our findings re-emphasise the concerns 
raised in these previous studies. 
As differences between male and female use of opioid analgesia in those with chronic pain 
were very apparent in the current study, we reiterate the call from Darnall, Stacey and Chou 
(2012) for future research to explore sex differences in more depth and to provide more 
detailed analysis on these themes[9]. The importance of sex differences is reflected in 
previous Australian research which demonstrated that females are more likely than males 
to intentionally overdose on opioid analgesia, specifically codeine [34]. Further, special 
consideration should be given to women of reproductive age. While it is imperative that 
females of reproductive age receive analgesic medication as medically indicated, it also is 
vital to allow them to make an informed decision on the risks and benefits of ongoing use of 
analgesic medication should pregnancy occur [33]. Additional epidemiological research is 
also needed to understand treatment option availability and utilisation, including the impact 
of treatment availability on daily functioning and quality of life of people living with pain 
conditions in Australia. 
The strengths of this study include the use of data collected as part of the 2011-12 
Australian NHS in a robust and rigorous manner by trained staff of the ABS, with a response 
rate of over 80%. We are limited however, by the fact that this survey relies mainly upon 
self-reported data. While this may be less of an issue for subjective, pain-related variables 
where self-report is considered the gold standard [35], self-report of medication use may 
not be as robust as medical record audit or linkage of prescription data [13]. If so, our 
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results will likely underestimate the proportion of the Australian population taking opioid 
and non-opioid analgesia. However, as participants were asked to physically provide the 
interviewer with all medications taken over the previous two weeks, this study’s findings are 
strengthened compared to self-reported medication use alone. Persons in hospital and 
other care facilities were not sampled, and the wide confidence intervals for some data are 
likely reflective of smaller sample sizes in the youngest and oldest age groups. Further 
analysis of chronic pain data was not possible due to data access restrictions. We were also 
limited by the specific questions asked within the survey. While chronic pain and medication 
use was asked of participants of all ages, questions about pain severity were only asked to 
participants aged ≥18 years. We were not able to distinguish whether the reported severity 
of bodily pain changed due to analgesia use. We were also not able to distinguish whether 
analgesia taken was prescribed or purchased ‘over the counter’. This survey is also unlikely 
to accurately capture non-adherent or illicit use of analgesic medications. 
Chronic pain and opioid analgesic medication use are important public health issues in 
Australia. Approximately 2.75 million Australians aged ≥15 years (15.4%) live with chronic or 
reoccurring pain. As there was no evidence to support an increase in chronic pain within the 
Australian population compared with previous estimates, the increased use of opioid 
analgesic medications noted within the literature thus appears consistent with changing 
treatment and/or prescribing patterns for these medications over time, potentially including 
for chronic pain. A higher percentage of females experienced chronic pain, moderate to very 
severe pain and reported use of opioid analgesic medications within almost every age 
group. We reiterate calls for future research to explore sex differences in the utilisation of 
analgesia in more depth. We also call for more detailed analysis relating to the use of opioid 
analgesia in those with chronic pain, including assessment of daily functioning, patient 
satisfaction and quality of life. 
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25 
27 
29 
1 
2 
3 Table 1: Severity of pain over the last four weeks in Australians aged ≥18 yearsa with chronic 
4 pain. Supplied by the Australian Bureau of Statistics, customised report 2015. 
5 
6 
7 
8 
9 Females Males 
10 
11 Pain severity in the last four weeks Estimate ‘000 (%) Estimate ‘000 (%) 
12 
b 
13 None 34.9 
(2.4b) 38.0 (3.0) 
14 Very mild - Mild 337.3 (23.4) 403.8 (31.6) 
15 Moderate - Very Severe 1,042.7 (72.2) 814.3 (63.8) 
16 
17 Total 1414.c 1,256.c 
18 
19 
20 
21 
22 
23 Notes: 
24 
a Bodily pain data only available for those aged 18 years and over 
26 b Relative Standard Error between 25- 50% 
28 c Totals do not equal 100%, data for persons who responded ‘not applicable’ or were 
30 unknown were not provided 
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41 
42 
43 
44 
45 
46  
47 
48 
1   
2  
3 Table 2: Pain severity in all Australians by age group (aged ≥15 years) 
4  
5 % 95% CI  % 95% CI 
6 Females 15 to 24 years No pain 25.24 (21.46-29.01) Males 15 to 24 years No pain 29.03 (25.49-32.57) 
7  Very mild to mild pain 30.07 (25.88-34.27)   Very mild to mild pain 32.21 (28.50-35.92) 
8  Moderate to very severe pain 16.22 (13.31-19.14)   Moderate to very severe pain 10.28 (7.63-12.92) 
9  Not asked/not known 28.47 (27.76-29.18)   Not asked/not known 28.49 (28.05-28.92) 
10 
11 25 to 34 years No pain 36.00 (32.61-39.40)  25 to 34 years No pain 38.22 (33.94-42.50) 
12  Very mild to mild pain 44.47 (41.11-47.84)   Very mild to mild pain 45.79 (41.68-49.91) 
13  Moderate to very severe pain 19.49 (17.30-21.69)   Moderate to very severe pain 15.35 (12.84-17.87) 
14  Not asked/not known 0.03 (0.00-0.10)   Not asked/not known 0.63 (0.00-1.26) 
15 35 to 44 years No pain 30.05 (27.02-33.09)  35 to 44 years No pain 32.74 (29.56-35.91) 
16  Very mild to mild pain 43.00 (39.70-46.30)   Very mild to mild pain 44.58 (41.46-47.69) 
17  Moderate to very severe pain 26.85 (23.74-29.95)   Moderate to very severe pain 22.32 (19.47-25.17) 
18  Not asked/not known 0.10 (0.05-0.30)   Not asked/not known 0.37 (0.00-0.74) 
19 45 to 54 years No pain 25.17 (22.09-28.24)  45 to 54 years No pain 33.46 (29.76-37.15) 
20  Very mild to mild pain 45.21 (42.49-47.94)   Very mild to mild pain 41.28 (37.56-45.01) 
21  Moderate to very severe pain 29.45 (26.68-32.21)   Moderate to very severe pain 24.50 (20.91-28.09) 
22  Not asked/not known 0.17 (0.00-0.42)   Not asked/not known 0.76 (0.03-1.49) 
23 55 to 64 years No pain 21.27 (18.62-23.92)  55 to 64 years No pain 29.87 (26.40-33.35) 
24 
25  Very mild to mild pain 39.72 (36.99-42.45)   Very mild to mild pain 40.04 (36.11-43.97) 
26  Moderate to very severe pain 38.12 (35.09-41.16)   Moderate to very severe pain 29.50 (25.57-33.43) 
27  Not asked/not known 0.89 (0.08-1.69)   Not asked/not known 0.58 (0.00-1.28) 
28 65 to 74 years No pain 23.67 (20.02-27.32)  65 to 74 years No pain 27.72 (24.26-31.17) 
29  Very mild to mild pain 35.04 (31.39-38.70)   Very mild to mild pain 35.83 (32.12-39.54) 
30  Moderate to very severe pain 40.48 (36.79-44.17)   Moderate to very severe pain 35.70 (31.84-39.57) 
31  Not asked/not known 0.81 (0.00-1.85)   Not asked/not known 0.75 (0.05-1.45) 
32 75 to 84 years No pain 21.55 (17.71-25.38)  75 to 84 years No pain 34.61 (27.90-41.32) 
33  Very mild to mild pain 27.01 (23.52-30.50)   Very mild to mild pain 37.11 (31.15-43.07) 
34  Moderate to very severe pain 49.94 (45.34-54.54)   Moderate to very severe pain 25.84 (20.68-31.01) 
35  Not asked/not known 1.51 (0.00-3.28)   Not asked/not known 2.43 (0.74-4.12) 
36 85 years + No pain 24.61 (17.21-32.01)  85 years + No pain 25.87 (14.87-36.86) 
37  Very mild to mild pain 25.59 (18.61-32.56)   Very mild to mild pain 32.37 (20.74-44.00) 
38  Moderate to very severe pain 41.83 (33.12-50.55)   Moderate to very severe pain 34.95 (21.87-48.04) 
40  Not asked/not known 7.97 (0.00-16.74)   Not asked/not known 6.81 (0.00-14.20) 
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1 
2 
3 Figure legends 
4 
5 
6 
7 Figure 1: Distribution of Australians aged ≥15 years with chronic or reoccurring pain 
8 compared to those using opioid analgesic medications, by 10-year age group and sex. 
9 
10 Supplied by the Australian Bureau of Statistics, Customised report 2015. Confidence 
11 intervals are not available for chronic pain data. 
12 
13 
14 
15 Figure 2: Distribution of analgesic medication use by Australians aged ≥15 years with chronic 
16 or reoccurring pain, by 10-year age group and sex, a) Opioid analgesia use, b) Non-opioid 
17 
18 analgesia use. Supplied by the Australian Bureau of Statistics, Customised report 2015. 
19 Confidence intervals are not available for chronic pain data. 
20 
21 
22 
23 Figure 3: Pain severity in Australians aged ≥15 years using opioid analgesic medications, by 
24 10-year age group and sex, a) Females b) Males. Error bars represent 95% confidence 
25 intervals 
26 
27 
28 
29 Figure 4: Pain severity in Australians aged ≥15 years using non-opioid analgesic medications, 
30 by 10-year age group and sex, a) Females b) Males. Error bars represent 95% confidence 
31 intervals. 
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